Immunotherapy for human cancer using heat shock protein-peptide complexes.
Heat shock proteins (HSPs) are primordial and abundant molecules expressed in all cells. Publications starting in 1984 have shown that immunization of mice, rats, and frogs with purified preparations of selected HSPs isolated from cancers leads to protective immunity against the cancer used as the source of the HSP. The basis of the tumor-specific immunogenicity of these molecules lies not in the molecules themselves but in the array of peptides, including antigenic peptides chaperoned by them. These experiments and the ideas derived from them form the basis of an approach to immunotherapy for human cancer that began in 1995 and is now in full swing.
Srivastava
Pramod K
PK
Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT 06030-1601, USA. srivastava@nso2.uchc.edu
D002986:Clinical Trials as Topic; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D007114:Immunization; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010446:Peptide Fragments / Q000276:immunology*
D006360:Heat-Shock Proteins; D010446:Peptide Fragments
Immunogenetics. 1994;39(2):93-8
8276462
Science. 1996 Jun 14;272(5268):1606-14
8658133
J Immunol. 2004 May 1;172(9):5277-86
15100266
J Immunol. 2004 May 15;172(10):6087-92
15128793
Nat Immunol. 2000 Aug;1(2):151-5
11248808
Immunity. 2004 Jan;20(1):95-106
14738768
J Immunol. 2004 Aug 1;173(3):1987-93
15265933
J Immunol. 2004 Oct 15;173(8):5130-7
15470057
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6128-33
15073331
J Cell Biol. 2003 Jun 23;161(6):1179-89
12821648
Cancer Res. 2004 Feb 15;64(4):1502-8
14973071
Tissue Antigens. 2004 Oct;64(4):442-51
15361121
Int J Cancer. 2003 Jun 10;105(2):226-31
12673684
J Clin Oncol. 2002 Oct 15;20(20):4169-80
12377960
J Biol Chem. 2004 Dec 3;279(49):51250-7
15371419
EMBO J. 2003 Nov 17;22(22):6127-36
14609958
J Biol Chem. 2004 Apr 16;279(16):16543-52
14754890
Blood. 2003 Sep 1;102(5):1806-14
12750160
J Virol. 2002 Jan;76(1):136-41
11739679
Immunity. 2001 Mar;14(3):303-13
11290339
Blood. 2003 May 15;101(10):4000-4
12531796
Cancer Immun. 2004 Apr 16;4:3
15086273
Cell. 1993 Nov 19;75(4):717-28
7902213
J Immunol. 2003 Oct 15;171(8):4054-61
14530326
Clin Cancer Res. 2003 Aug 15;9(9):3235-45
12960108
Cancer Immunol Immunother. 2003 Apr;52(4):226-34
12669247
Exp Cell Res. 2004 Jul 1;297(1):108-17
15194429
Cancer Res. 2001 Jan 1;61(1):222-7
11196165
Int Immunol. 2004 Apr;16(4):597-605
15039390
J Immunol. 2004 Mar 15;172(6):3719-24
15004176
J Exp Med. 2002 Dec 2;196(11):1447-59
12461080
J Immunol. 2002 Nov 15;169(10):5424-32
12421917
J Immunol. 1999 Nov 15;163(10):5178-82
10553037
Blood. 2003 Apr 1;101(7):2810-5
12446445
J Immunol. 2003 Oct 1;171(7):3467-74
14500642
Annu Rev Immunol. 2002;20:395-425
11861608